Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions are as follows:

	December 31, 2019
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	2,223	$	—	$	2,223
Other current assets	9,698		—		9,698
Property, plant and equipment, net	51,975		—		51,975
Intangible assets, net	20,891		4,383		25,274
Investments in affiliates	—		7,817		7,817
Right-of-use assets	13,622		—		13,622
Other noncurrent assets	212		—		212
Total assets held for sale	$	98,621	$	12,200	$	110,821
Liabilities
Deferred revenue, current (1)	$	8,723	$	—	$	8,723
Operating lease liabilities, current	2,459		—		2,459
Other current liabilities	3,058		41		3,099
Deferred revenue, net of current portion (2)	19,410		—		19,410
Operating lease liabilities, net of current portion	12,623		—		12,623
Other long-term liabilities	1,019		—		1,019
Total liabilities held for sale	$	47,292	$	41	$	47,333

(1) Includes deferred revenue, current, from related parties of $1,243.

(2) Includes deferred revenue, net of current portion, from related parties of $6,836.

	December 31, 2018
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	5,892	$	—	$	5,892
Other current assets	3,263		—		3,263
Property, plant and equipment, net	41,978		—		41,978
Intangible assets, net	31,782		8,547		40,329
Investments in affiliates	—		16,720		16,720
Goodwill	55,958		—		55,958
Other noncurrent assets	1,376		—		1,376
Total assets held for sale	$	140,249	$	25,267	$	165,516
Liabilities
Deferred revenue, current (1)	$	4,466	$	—	$	4,466
Other current liabilities	3,874		—		3,874
Deferred revenue, net of current portion (2)	7,482		—		7,482
Other long-term liabilities	3,476		—		3,476
Total liabilities held for sale	$	19,298	$	—	$	19,298

(1) Includes deferred revenue, current, from related parties of $443.

(2) Includes deferred revenue, net of current portion, from related parties of $7,455.

The following tables present the financial results of discontinued operations:

	Year Ended December 31, 2019
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	12,307		$	—		$	12,307
Operating expenses (2)	116,091			10,794			126,885
Operating loss	(103,784		)	(10,794		)	(114,578		)
Other expense, net	(272		)	—			(272		)
Equity in net loss of affiliates	—			(4,314		)	(4,314		)
Loss before income taxes	(104,056		)	(15,108		)	(119,164		)
Income tax benefit	3,005			—			3,005
Loss from discontinued operations	$	(101,051	)	$	(15,108	)	$	(116,159	)

(1) Includes revenue recognized from related parties of $3,042.

(2) Includes the impairment charge of $89,679 related to the Transactions discussed above.

	Year Ended December 31, 2018
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	9,396		$	—		$	9,396
Operating expenses (2)	111,039			470			111,509
Operating loss	(101,643		)	(470		)	(102,113		)
Other expense, net	(1,757		)	—			(1,757		)
Equity in net loss of affiliates	—			(2,622		)	(2,622		)
Loss before income taxes	(103,400		)	(3,092		)	(106,492		)
Income tax benefit	6,103			—			6,103
Loss from discontinued operations	$	(97,297	)	$	(3,092	)	$	(100,389	)

(1) Includes revenue recognized from related parties of $4,665.

(2) Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the Aedes Aegypti mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.

	Year Ended December 31, 2017
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	11,518		$	—		$	11,518
Operating expenses (2)	53,028			470			53,498
Operating loss	(41,510		)	(470		)	(41,980		)
Other expense, net	(7,506		)	—			(7,506		)
Equity in net loss of affiliates	—			(1,847		)	(1,847		)
Loss before income taxes	(49,016		)	(2,317		)	(51,333		)
Income tax benefit	4,952			—			4,952
Loss from discontinued operations	$	(44,064	)	$	(2,317	)	$	(46,381	)

(1) Includes revenue recognized from related parties of $8,185.

(2) Includes an impairment charge of $2,950 recorded as part of its annual impairment assessment of indefinite-lived intangible assets.

The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying consolidated statements of cash flows.

	Year Ended December 31,
	2019			2018			2017
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	5,107		$	9,007		$	9,536
Impairment loss	89,679			60,504			2,950
Unrealized and realized depreciation on equity securities and preferred stock, net	458			1,927			7,544
Equity in net loss of EnviroFlight	4,314			2,622			1,847
Stock-based compensation expense	2,507			3,872			4,683
Deferred income taxes	(2,710		)	(5,703		)	(4,575		)
Cash flows from investing activities
Investments in EnviroFlight	(2,000		)	(12,250		)	(4,750		)
Purchases of property, plant and equipment	(23,326		)	(21,191		)	(13,455		)

Also see Note 23 below.

Equity Method Investments

The Company accounted for its investment in EnviroFlight using the equity method of accounting.

The Company accounted for its equity securities held in Oragenics, one of its collaborators and a related party, using the fair value option. Oragenics was considered an equity method investment through September 30, 2018.

Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.

	December 31,
	2019		2018
Current assets	$	703	$	5,119
Noncurrent assets	30,549		29,326
Total assets	31,252		34,445
Current liabilities	2,352		1,005
Non-current liabilities	88		—
Total liabilities	2,440		1,005
Net assets	$	28,812	$	33,440

	Year Ended December 31,
	2019			2018			2017
Revenues	$	510		$	268		$	254
Operating expenses	9,159			12,709			10,671
Operating loss	(8,649		)	(12,441		)	(10,417		)
Other, net	21			39			(8		)
Net loss	$	(8,628	)	$	(12,402	)	$	(10,425	)

Where applicable, the notes to the consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.